On Target Laboratories, LLC   Report issue

Contributed to NME For profit Phase 3
Founded: Northbrook IL United States (2010)
Status: No NME R&D (2010)

Organization Overview

First Clinical Trial
2014
NCT02317705
First Marketed Drug
2021
pacritinib (Vonjo)
First NDA Approval
2021
pacritinib (Vonjo)
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

On Target Laboratories, LLC | ON TARGET LABS

Active Ingredients

Marketed Drugs (1)

pacritinib (Vonjo) (2021 NDA)

Drugs in Phase 3 Trials (1)

pacritinib (Vonjo) (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 1)

Arthritis, Rheumatoid (Phase 1)

Carcinoma, Ovarian Epithelial (Phase 2)

Lung Neoplasms (Phase 3)

Ovarian Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 1